Physician profile
Jean-Luc C Urbain
NPI 1548588759
$3,888.62
in general payments reported to CMS, 2019-2025
10 companies · $603 in 2025
The $603 reported for 2025 was more than what a typical Nuclear Imaging & Therapy provider received nationally (typical 2025 total: $122).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $398 · 2020: $2,000 · 2021: $259 · 2022: $302 · 2023: $147 · 2024: $180 · 2025: $603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $930.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $930.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jubilant Draximage INC. | $2,000.00 | 2020 | |
| Ge Healthcare | $606.54 | 2019-2025 | |
| Telix Pharmaceuticals | $337.34 | 2024-2025 | Illuccix, Gozellix |
| United Imaging Healthcare North America, INC. | $303.16 | 2025 | N/A, N/A |
| United Imaging Healthcare North America LLC | $150.00 | 2019 | |
| Voximetry, INC. | $147.40 | 2023 | Torch |
| Cardinal Health 414 LLC | $129.57 | 2022-2024 | |
| Siemens Medical Solutions USA, INC. | $109.75 | 2022 | |
| Advanced Accelerator Applications | $84.03 | 2019 | |
| Progenics Pharmaceuticals, INC. | $20.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jean-Luc Urbain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.